Sustained reduction of vein graft neointima formation by ex vivo TIMP-3 gene therapy

Circulation

Volumn 124, Issue 11 SUPPL. 1, 2011, Pages

  George, Sarah J ^a   Wan, Song ^b   Hu, Jia ^b   MacDonald, Robert ^c   Johnson, Jason L ^a   Baker, Andrew H ^c  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

coronary artery bypass grafting; gene therapy; metalloproteinases; neointima formation; vein graft failure

Indexed keywords

ADENOVIRUS VECTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; CAROTID ARTERY; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; HISTOLOGY; MALE; NONHUMAN; PRIORITY JOURNAL; SAPHENOUS VEIN; THERAPY EFFECT; VEIN GRAFT; VEIN GRAFT INTIMAL THICKENING; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; CAROTID ARTERIES; CELL MOVEMENT; ENDOTHELIUM, VASCULAR; GENE THERAPY; MODELS, ANIMAL; MUSCLE, SMOOTH, VASCULAR; NEOINTIMA; SAPHENOUS VEIN; SWINE; TIME FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TREATMENT OUTCOME; VASCULAR GRAFTING;

EID: 80052735881     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.110.012732     Document Type: Article

References (30)

1. American Heart Association. Heart Disease and Stroke Statistics. http://americanheart.org/downloadable/heart/HeartStrokeUpdate-2010. pdf. 2010.
2. Motwani JG, Topol EJ. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation. 1998;97: 916-931. (Pubitemid 28113931)
3. Lazar HL. Role of statin therapy in the coronary bypass patient. Ann Thoracic Surg. 2004;78:730-740. (Pubitemid 38980821)
4. Zempo N, Kenagy RD, Au T, Bendeck M, Clowes MM, Reidy MA, Clowes AW. Matrix metalloproteinases of vascular wall cells are increased in balloon-injured rat carotid. J Vasc Surg. 1994;20:209-217. (Pubitemid 24260589)
5. Southgate KM, Fisher M, Banning AP, Thurston VJ, Baker AH, Fabunmi RP, Groves PH, Davies M, Newby AC. Upregulation of basement membrane-degrading metalloproteinase secretion after balloon injury of pig carotid arteries. Circ Res. 1996;79:1177-1187. (Pubitemid 26404150)
6. Southgate KM, Mehta D, Izzat MB, Newby AC, Angelini GD. Increased secretion of basement membrane-degrading metalloproteinases in pig saphenous vein into carotid artery interposition grafts. Arterioscler Thromb Vasc Biol. 1999;19:1640-1649. (Pubitemid 29323822)
7. George SJ, Zaltsman AB, Newby AC. Surgical preparative injury and neointima formation increase MMP-9 expression and MMP-2 activation in human saphenous vein. Cardiovasc Res. 1997;33:447-459. (Pubitemid 27072650)
8. Newby AC. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev. 2005;85:1-31. (Pubitemid 40171256)
9. Forough R, Koyama N, Hasenstab D, Lea H, Clowes M, Nikkari ST, Clowes AW. Overexpression of tissue inhibitor of matrix metalloproteinase-1 inhibits vascular smooth muscle cell functions in vitro and in vivo. Circ Res. 1996;79:812-820. (Pubitemid 26317829)
10. George SJ, Johnson JL, Angelini GD, Newby AC, Baker AH. Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits SMC migration and neointima formation in human saphenous vein. Hum Gene Ther. 1998;9:867-877. (Pubitemid 28197373)
11. George SJ, Baker AH, Angelini GD, Newby AC. Gene transfer of tissue inhibitor of metalloproteinase-2 inhibits metalloproteinase activity and neointima formation in human saphenous veins. Gene Ther. 1998;5: 1552-1560. (Pubitemid 28517383)
12. Cheng L, Mantile G, Pauly R, Nater C, Felici A, Monticone R, Bilato C, Gluzband YA, Crow MT, Stetler-Stevenson W, Capogrossi MC. Adenovirus-mediated gene transfer of the human tissue inhibitor of metalloproteinase-2 blocks vascular smooth muscle cell invasiveness in vitro and modulates neointimal development in vivo. Circulation. 1998; 98:2195-2201. (Pubitemid 28527480)
13. Dollery CM, Humphries SE, McClelland A, Latchman DS, McEwan JR. Expression of tissue inhibitor of matrix metalloproteinases 1 by use of an adenoviral vector inhibits smooth muscle cell migration and reduces neointimal hyperplasia in the rat model of vascular balloon injury. Circulation. 1999;99:3199-3205. (Pubitemid 29289087)
14. George SJ, Lloyd CT, Angelini GD, Newby AC, Baker AH. Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3. Circulation. 2000;101:296-304. (Pubitemid 30054157)
15. Baker AH, Zaltsman AB, George SJ, Newby AC. Divergent effects of tissue inhibitor of metalloproteinase-1,-2, or-3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. J Clin Invest. 1998;101:1478-1487. (Pubitemid 28145266)
16. Angelini GD, Bryan AI, Williams HMJ, Morgan R, Newby AC. Distention promotes platelet and leukocyte adhesion and reduces short-term patency in pig arteriovenous bypass grafts. J Thorac Cardiovasc Surg. 1990;99:433-439. (Pubitemid 20097769)
17. Wan S, George SJ, Nicklin SA, Yim APC, Baker AH. Overexpression of p53 increases lumen size and blocks neointima formation in porcine interposition vein grafts. Mol Ther. 2004;9:689-698. (Pubitemid 38660422)
18. Wan S, Yim APC, Johnson JL, Shukla N, Angelini GD, Smith FCT, Dashwood MR, Jeremy JY. The endothelin-1A receptor antagonist BSF 302146 is a potent inhibitor of neointimal and medial thickening in porcine saphenous vein-carotid artery interposition grafts. J Thorac Cardiovasc Surg. 2004;127:1317-1322. (Pubitemid 38560593)
19. Kritz AB, Yu J, Wright PL, Wan S, George SJ, Halliday C, Kang N, Sessa WC, Baker AH. In vivo modulation of Nogo-B attenuates neointima formation. Mol Ther. 2008;16:1798-1804.
20. Wan S, Shukla N, Angelini GD, Yim APC, Johnson JL, Jeremy JY. Nitric oxide-donating aspirin (NCX 4016) inhibits neointimal thickening in a pig model of saphenous vein carotid artery interposition grafting: a comparison with aspirin and morpholinosydnonimine (SIN-1). J Thorac Cardiovasc Surg. 2007;134:1033-1039. (Pubitemid 47445624)
21. Jeremy JY, Bulbulia R, Johnson JL, Gadsdon P, Vijayan V, Shukla N, Smith FC, Angelini GD. A bioabsorbable (polyglactin), nonrestrictive, external sheath inhibits porcine saphenous vein graft thickening. J Thorac Cardiovasc Surg. 2004;127:1766-1772. (Pubitemid 38725459)
22. Zenati MA, Shroyer AL, Collins JF, Hattler B, Ota T, Almassi GH, Amidi M, Novitzky D, Grover FL, Sonel AF. Impact of endoscopic versus open saphenous vein harvest technique on late coronary artery bypass grafting patient outcomes in the ROOBY (Randomized On/Off Bypass) Trial. J Thorac Cardiovasc Surg. 2011;141:338-344.
23. PREVENT IV Investigators. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA. 2005;294:2446-2454.
24. Souza DS, Johansson B, Bojö L, Karlsson R, Geijer H, Filbey D, Bodin L, Arbeus M, Dashwood MR. Harvesting the saphenous vein with surrounding tissue for CABG provides long-term graft patency comparable to the left internal thoracic artery: results of a randomized longitudinal trial. J Thorac Cardiovasc Surg. 2006;132:373-378.
25. Shah PJ, Gordon I, Fuller J, Seevanayagam S, Rosalion A, Tatoulis J, Raman JS, Buxton BF. Factors affecting saphenous vein graft patency: clinical and angiographic study in 1402 symptomatic patients operated on between 1977 and 1999. J Thorac Cardiovasc Surg. 2003;126: 1972-1977. (Pubitemid 38020761)
26. Hayward PAR, Gordon IR, Hare DL, Matalanis G, Horrigan ML, Rosalion A, Buxton BF. Comparable patencies of the radial artery and right internal thoracic artery or saphenous vein beyond 5 years: results from the Radial Artery Patency and Clinical Outcomes trial. J Thorac Cardiovasc Surg. 2010;139:60-67.
27. Achouh P, Ould Isselmou K, Boutekad Jirt R, D'Alessandro C, Pagny J, Fouquet R, Fabiani J, Acar C. Reappraisal of a 20-year experience with the radial artery for coronary bypass grafting [abstract]. Presented at the American Heart Association Scientific Sessions 2010 (November 13-17, 2010, Chicago, IL).
28. Channon KM, Fulton GJ, Gray JL, Annex BH, Shetty GA, Blazing MA, Peters KG, Hagen PO, George SE. Efficient adenoviral gene transfer to early venous bypass grafts: comparison with native vessels. Cardiovasc Res. 1997;35:505-513. (Pubitemid 27469412)
29. Newman KD, Dunn PF, Owens JW, Schulick AH, Virmani R, Sukhova G, Libby P Dichek D. Adenovirus-mediated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation, and neointimal hyperplasia. J Clin Invest. 1995;96:2955-2965.
30. Hedman M, Hartikainen J, Yla-Herttuala. Progress and prospects to cardiovascular gene therapy clinical trials. Gene Ther. April 14, 2011. DOI: 10.1038/gt.2011.43. http://www.nature.com/gt/index.html. Accessed August 23, 2011.